On November 18, DUALITYBIO-B fell 4.34% in Regular Trading, trading at HK$89.3, with turnover of HK$6.40 million.
The clearest disclosed catalyst is continued post-buyback weakness, as the market kept digesting the earlier clinical-data-related disruption despite ongoing company repurchases and chairman share purchases.
Company filings show DUALITYBIO-B disclosed on November 16 that it repurchased 45,400 shares on the Hong Kong Stock Exchange at HK$96.00 to HK$98.95 per share for about HK$4.43 million, with the shares to be held in treasury. This followed multiple buybacks earlier in November and repeated on-market purchases by Chairman Zhu Zhongyuan since late October, including a November 10 purchase at HK$107.276 per share that lifted his stake to 17.66%. Even so, the latest share price has moved below both the recent buyback range and the chairman's accumulation range, indicating near-term support remains limited.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments